drugset / Trial / NCT04158076

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine

NCT04158076

Phase 3 Completed 131 enrolled Addpharma Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine in patients with primary hypercholesterolemia and essential hypertension.

Timeline

Start
2020-01-23
Primary completion
2021-01-14
Completion
2021-01-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe/Rosuvastatin Unknown Oral
Comparator Telmisartan Other / unclassified Oral
Subject Telmisartan/Amlodipine Unknown 5 mg Oral
Subject Telmisartan/Amlodipine Unknown 80 mg Oral